Syneron Medical Ltd. (NASDAQ:ELOS) has received a consensus broker rating score of 1.50 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and three have given a strong buy recommendation to the company. Syneron Medical’s rating score has declined by 50% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 12 month consensus price target of $11.20 for the company and are predicting that the company will post ($0.02) EPS for the current quarter, according to Zacks. Zacks has also given Syneron Medical an industry rank of 97 out of 265 based on the ratings given to related companies.
A number of research firms have weighed in on ELOS. Brean Capital reissued a “buy” rating and issued a $13.00 target price on shares of Syneron Medical in a research note on Monday, August 8th. Leerink Swann downgraded shares of Syneron Medical from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $9.40 to $7.80 in a report on Friday, August 5th. Finally, Zacks Investment Research upgraded shares of Syneron Medical from a “sell” rating to a “hold” rating in a report on Monday, July 25th.
A number of hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC increased its stake in Syneron Medical by 5.8% in the first quarter. Geode Capital Management LLC now owns 21,010 shares of the company’s stock valued at $152,000 after buying an additional 1,159 shares during the period. Hilton Capital Management LLC bought a new stake in Syneron Medical during the first quarter valued at $117,000. Royce & Associates LP increased its stake in Syneron Medical by 7.5% in the first quarter. Royce & Associates LP now owns 713,159 shares of the company’s stock valued at $5,213,000 after buying an additional 50,000 shares during the period. Brandes Investment Partners LP increased its stake in Syneron Medical by 8.5% in the second quarter. Brandes Investment Partners LP now owns 2,723,535 shares of the company’s stock valued at $20,944,000 after buying an additional 214,089 shares during the period. Finally, Marshall Wace LLP bought a new stake in Syneron Medical during the second quarter valued at $1,473,000. Hedge funds and other institutional investors own 72.44% of the company’s stock.
Shares of Syneron Medical (NASDAQ:ELOS) opened at 7.16 on Thursday. The stock’s market cap is $252.57 million. The firm’s 50-day moving average price is $6.73 and its 200-day moving average price is $7.06. Syneron Medical has a 12-month low of $6.10 and a 12-month high of $8.47.
Syneron Medical (NASDAQ:ELOS) last released its earnings results on Thursday, August 4th. The company reported $0.09 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.03. Syneron Medical had a negative net margin of 1.42% and a positive return on equity of 2.88%. The business had revenue of $75 million for the quarter, compared to analyst estimates of $75.72 million. During the same period last year, the company posted $0.07 EPS. The business’s revenue was up 2.0% on a year-over-year basis. On average, analysts forecast that Syneron Medical will post $0.27 EPS for the current fiscal year.
About Syneron Medical
Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneron Medical Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneron Medical Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.